Frequently Asked Questions About MANE

How is MANE valued?

Veradermics, Incorporated (MANE)'s valuation is shown across multiple multiples on this page — P/E, P/B, P/S, EV/EBITDA, P/FCF — with both current and historical context. When trailing earnings are negative, forward-looking multiples and revenue / cash-flow ratios become more relevant.

Is MANE undervalued or overvalued?

Veradermics, Incorporated's current valuation multiples are compared against the stock's own historical range and against sector peers on this page. A multiple in the lowest percentile of its 10-year history is typically considered undervalued (with caveats — the analyst price target card adds another data point).

What is the analyst price target for MANE?

The Wall Street price-target card on this page shows the consensus 12-month price target for Veradermics, Incorporated (MANE), the high and low range, and the implied upside or downside vs the current share price. Individual analyst ratings are listed below the target range.

What is MANE's EV/EBITDA?

Veradermics, Incorporated's enterprise-value-to-EBITDA multiple is shown on this page. EV/EBITDA is capital-structure neutral (unlike P/E) and is especially useful for comparing companies with different debt levels — a common screen for value investors.

MANE (Veradermics, Incorporated) is a recent IPO.

It began trading on February 4, 2026, giving it under six months of public history. Many charts and metrics below are sparse or empty until more price, financial, and analyst history accumulates — the affected sections are flagged individually so you can tell limited history from missing data.

MANE

Veradermics, Incorporated

NYSE·Biotechnology · Healthcare

$109.49$3.45+3.25%

After hours·$109.42−0.06%

Market cap$4.57B·Market closed·Jul 21 8:00 PM UTC

Wall Street Targets

PRO

Aggregate Wall Street consensus, the per-analyst targets table with direction tagging, and a dividend-aware total-return framing — all on one card.

Click below to see what's inside, then upgrade to unlock for MANE and 80,000+ other tickers.

Analyst ratings and price targets reflect sell-side opinion — not a Dividend Data endorsement. Forward-looking estimates may not be achieved.

P/E Ratio

Current—

Daily data isn’t available yet — MANE IPO’d February 4, 2026, so there isn’t enough history for this view. It will fill in as trading and filing history accumulate.

Chart tools

Open P/E Ratio in Chart Builder to fine-tune colors, labels, and timeframe, then download a high-res PNG.

Y-axis

Export Chart

P/B Ratio

Current—

Daily data isn’t available yet — MANE IPO’d February 4, 2026, so there isn’t enough history for this view. It will fill in as trading and filing history accumulate.

Chart tools

Open P/B Ratio in Chart Builder to fine-tune colors, labels, and timeframe, then download a high-res PNG.

Y-axis

Export Chart

P/S Ratio

Current—

Daily data isn’t available yet — MANE IPO’d February 4, 2026, so there isn’t enough history for this view. It will fill in as trading and filing history accumulate.

Chart tools

Open P/S Ratio in Chart Builder to fine-tune colors, labels, and timeframe, then download a high-res PNG.

Y-axis

Export Chart

P/OCF Ratio

Current—

Daily data isn’t available yet — MANE IPO’d February 4, 2026, so there isn’t enough history for this view. It will fill in as trading and filing history accumulate.

Chart tools

Open P/OCF Ratio in Chart Builder to fine-tune colors, labels, and timeframe, then download a high-res PNG.

Y-axis

Export Chart

P/FCF Ratio

Current—

Daily data isn’t available yet — MANE IPO’d February 4, 2026, so there isn’t enough history for this view. It will fill in as trading and filing history accumulate.

Chart tools

Open P/FCF Ratio in Chart Builder to fine-tune colors, labels, and timeframe, then download a high-res PNG.

Y-axis

Export Chart

PEG Ratio

Current—

Daily data isn’t available yet — MANE IPO’d February 4, 2026, so there isn’t enough history for this view. It will fill in as trading and filing history accumulate.

Chart tools

Open PEG Ratio in Chart Builder to fine-tune colors, labels, and timeframe, then download a high-res PNG.

Y-axis

Export Chart

EV/EBITDA

Current—

Chart tools

Open EV/EBITDA in Chart Builder to fine-tune colors, labels, and timeframe, then download a high-res PNG.

Y-axis

Export Chart

3 rows


2025Current	−18.61x
2024	−291.37x
2023	−460.97x

Frequently Asked Questions About MANE

How is MANE valued?: Veradermics, Incorporated (MANE)'s valuation is shown across multiple multiples on this page — P/E, P/B, P/S, EV/EBITDA, P/FCF — with both current and historical context. When trailing earnings are negative, forward-looking multiples and revenue / cash-flow ratios become more relevant.
Is MANE undervalued or overvalued?: Veradermics, Incorporated's current valuation multiples are compared against the stock's own historical range and against sector peers on this page. A multiple in the lowest percentile of its 10-year history is typically considered undervalued (with caveats — the analyst price target card adds another data point).
What is the analyst price target for MANE?: The Wall Street price-target card on this page shows the consensus 12-month price target for Veradermics, Incorporated (MANE), the high and low range, and the implied upside or downside vs the current share price. Individual analyst ratings are listed below the target range.
What is MANE's EV/EBITDA?: Veradermics, Incorporated's enterprise-value-to-EBITDA multiple is shown on this page. EV/EBITDA is capital-structure neutral (unlike P/E) and is especially useful for comparing companies with different debt levels — a common screen for value investors.

2025Current

−18.61x

2024

−291.37x

2023

−460.97x

Veradermics, Incorporated

Frequently Asked Questions About MANE

Veradermics, Incorporated

Wall Street Targets

P/E Ratio

P/B Ratio

P/S Ratio

P/OCF Ratio

P/FCF Ratio

PEG Ratio

EV/EBITDA

Frequently Asked Questions About MANE

Wall Street Targets

P/E Ratio

P/E Analyzer

P/B Ratio

P/S Ratio

P/OCF Ratio

P/FCF Ratio

PEG Ratio

EV/EBITDA

P/E Analyzer